Content provided in partnership with
Once-a-day pill falls short
Advocate, The, Oct 11, 2005
People with HIV have long waited for a once-a-day pill to treat the disease, and it looked like they might finally get it this year. That was until pharmaceutical giant Gilead Sciences announced in August that a second attempt to combine its combination anti-HIV medication Truvada with Bristol-Myers Squibb's Sustiva had failed.
- Most Popular Articles in News
- The Ten Best Laptop bags
- Tata plans cheapest-ever car for Indian market
- GLOBALIZATION AND THE DEVELOPMENT OF UNDERDEVELOPMENT OF THE THIRD WORLD
- Corn is good for you; Corn is not only a tasty treat, but also a cereal that ...
- THE 50 BEST STYLISH HANDBAGS TO CARRY
- More »
The latest formulation of the drugs did not achieve the same bioequivalency as individual doses of the medications, Gilead officials said. The two companies are now considering new approaches and hope to file for Food and Drug Administration approval in the first half of 2006.
COPYRIGHT 2005 Liberation Publications, Inc.
COPYRIGHT 2005 Gale Group
Find Research Guides for:
Find Featured Titles for: Reference
- Academe
- African American Review
- African Arts
- African Studies Review
- Afro-Americans in New York Life and History
- Alabama Heritage
- Alabama Review
- American Mathematical Monthly, The
- Anglican Theological Review
- Annals of Dyslexia
- Arab Studies Quarterly (ASQ)
- Auk, The
- Australian Journal of Anthropology, The
- Christian Century
- Natural History